1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
GC Biopharma Corp.

GC Biopharma Corp.

KKRX:006280
132,200.00
KRW
+1,200.00
(+0.92%)
-5,559.49EPS
1.37TMarket Cap
Nov 03Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
77,831.35
84,351.69
90,617.22
103,697.33
112,835.92
116,973.22
119,014.21
131,781.28
134,746.56
149,945.12
142,497.41
147,213.07
174,679.84
172,078
Basic EPS, GAAP
6,140
7,260
8,213
5,451
4,665
3,017
-319
7,101
10,796
5,735
-2,333
-2,303
-410
-4,372.26
Free Cash Flow per Basic Share
-5,341.28
-1,207.02
-7,817.52
-8,691.97
202.3
-4,436.29
-9,412.08
-5,731.83
213.82
2,143.54
-11,516.55
-8,399.69
-510.17
4,931.49
Dividend per Share
1,129.76
1,274.66
1,299.7
1,774.59
1,343.12
1,342.99
1,085.54
1,114.36
1,621.97
2,101.57
2,174.7
1,711.66
1,651.93
1,719.91
Book Value per Share
71,182.96
77,198.63
82,746.24
87,010.94
91,141.41
92,840.8
91,887.77
98,002.82
111,692.86
116,367.45
113,924.12
109,754.26
106,673.41
108,356.51
Tangible Book Value per Share
67,297.69
72,473.99
77,537.8
80,561.07
83,438.31
84,005.35
82,861.59
88,403.04
87,387.11
89,068.9
84,319.65
82,821.77
77,120.35
79,295.48
Basic Weighted Avg Shares
11
12
12
12
11
11
11
11
11
11
11
11
11
11
Sales/Revenue/Turnover
888,168
975,327
1,047,812
1,197,904
1,287,916
1,334,878
1,357,117
1,504,115
1,537,826
1,711,313
1,626,644
1,679,892
1,991,279
1,963,952
Operating Margin (%)
8.87
9.94
8.75
6.55
7.01
3.76
3.07
3.34
4.79
4.75
2.12
1.91
3.47
2.41
Depreciation Expense
18,425
23,521
28,426
31,073
36,724
40,130
46,666
48,791
55,904
65,096
75,899
81,034
87,655
85,567
Net Income, GAAP
70,066
83,945
94,967
62,970
53,247
34,429
-3,638
81,049
123,212
65,453
-26,632
-26,280
-4,674
-49,901
Effective Tax Rate (%)
20.87
25.6
25.76
18.06
21.4
31.71
- -
14.71
20.64
19.03
- -
- -
- -
- -
Profit Margin (%)
7.89
8.61
9.06
5.26
4.13
2.58
-0.27
5.39
8.01
3.82
-1.64
-1.56
-0.23
-2.54
Working Capital
351,967
328,511
435,726
498,080
666,482
589,948
560,357
542,640
542,738
439,699
170,232
432,359
224,585
348,703
LT Debt
20,590
38,025
74,000
149,545
306,989
263,320
342,817
264,552
371,312
376,547
191,426
435,917
358,597
404,507
Total Equity
839,409
920,627
997,704
1,059,011
1,108,713
1,126,207
1,184,077
1,269,306
1,499,757
1,566,642
1,539,863
1,481,016
1,394,273
1,326,195
Return on Invested Capital (%)
7.43
7.21
6.01
5.18
5.16
2.37
- -
2.44
2.94
3.07
- -
- -
- -
- -
Return on Capital (%)
8.4
8.59
8.86
5.35
4.01
2.77
- -
4.66
6.06
3.6
- -
- -
- -
- -
Return on Common Equity (%)
9.37
9.79
10.27
6.46
5.24
3.28
-0.35
7.48
10.3
5.03
-2.03
-2.06
-0.38
-3.97

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
623,547
558,905
534,341
LT Borrowings
253,501
260,645
310,435
LT Finance Leases
105,096
94,776
94,072
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
1,814,687
1,630,936
1,371,858

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,370,388
1,297,835
1,358,102
Cash, Cash Equivalents & STI
50,804
42,727
44,658
Accounts Receivable, Net
402,689
371,080
351,555
Inventories
891,582
857,519
886,886
Total Current Liabilities
1,145,803
1,039,429
1,009,399
Payables & Accruals
- -
- -
- -
ST Debt
623,547
558,905
534,341
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.6%
2.25%
-5.86%
Free Cash Flow
-227.03%
8.08%
-93.93%
Net Income, GAAP
-274.23%
-43.82%
-82.22%
Sales/Revenue/Turnover
6.84%
6.08%
18.54%
Total Cash Common Dividend
4.84%
10.74%
-3.59%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
356,810
417,363
464,866
440,854
1,679,892
2025
383,779
500,260
609,486
497,755
1,991,279
2026
435,532
421,180
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-2,218
-608
2,915
-2,391.48
-2,303
2025
2,602
3,329
1,397.07
-7,736.97
-410
2026
1,793.87
173.78
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1,711.66
2025
- -
- -
- -
- -
1,651.93
2026
2.36
1,717.56
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Eun-Cheol Huh
Full Time Employees
2,351
Sector
Health technology
Industry
Pharmaceuticals: major
Address
107, Ihyeon-ro 30beon-gil, Giheung-gu Yongin-si GY South Korea 16924
IPO Date
Aug 1, 1989
Website
gccorp.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
GC Biopharma Corp. (006280.KS) manufactures and markets biopharmaceutical products with a focus on plasma-derived therapeutics, recombinant proteins, vaccines, and immunology treatments in South Korea and internationally. The company offers an extensive portfolio of plasma derivatives including Albumin-GCC injection for hypoalbuminemia and shock, Antithrombin-III for hereditary deficiencies, Fibrinogen for hypofibrinogenemia, Gamma Globulin and I.V.-Globulin SN for immune deficiencies, Hepabig and I.V. Hepabig for hepatitis B prevention and recurrence, and Greenplast Q for tissue sealing; recombinant products such as GreenGene F and GreenGene for hemophilia A, Facnyne for hemophilia B, Green-VIII for factor VIII supply, and Hunterase for Hunter syndrome; vaccines like GCFLU Quadrivalent and GC FLU pre-filled syringes for influenza prevention, Varicella Vaccine, Sero-Tet for tetanus prophylaxis, and BARYCELA chickenpox vaccine; immunology therapies including Immuncell-LC for liver cancer, Histobulin for bronchial asthma, and IV-Globulin (Alyglo) for autoimmune conditions; over-the-counter drugs such as Acustop Cataplasma, Kenhancer plaster, Zenol Cool Type, and Shinbaro for pain relief and anti-inflammation. Founded in 1967 and headquartered in Yongin-si, Gyeonggi-do, South Korea, GC Biopharma Corp. operates as a subsidiary of Green Cross Holdings Corporation, maintains manufacturing facilities in South Korea including Hwasun, Jeollanam-do, and conducts R&D in rare diseases, bleeding disorders, lysosomal storage diseases, oncology, and next-generation mRNA/LNP platforms while distributing to over 50 countries. Recent developments include securing CMO rights for Curevo Vaccine's shingles vaccine amezosvatein in October 2025 to expand its vaccine portfolio; acquiring three orphan hematology programs including subcutaneous Marzeptacog alfa (MarzAA) from Catalyst Biosciences in February 2023 for Phase 3-ready rare bleeding disorder treatments; advancing clinical trials for Hunterase ICV intracerebroventricular injection in Korea following Japan approval; pursuing U.S. approval and launch of intravenous immunoglobulin GC5107 (Alyglo) to enter the plasma market; and maintaining a research agreement with Novelty Nobility for antibody therapeutics targeting geographic atrophy.

Company News

Company News APIChatGPT

  • headlinesoftoday.com

    GC Biopharma Receives WHO Pre-Qualification for Filling and Finish Plant in Ochang, South Korea